Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

K. Litton, Jennifer; S. Rugo, Hope; Ettl, Johannes; A. Hurvitz, Sara; Gonçalvès, Anthony; Lee, Kyung-Hun; Fehrenbacher, Louis; Yerushalmi, Rinat; A. Mina, Lida; Martín, Miguel; Roché, Henri; Im, Young‐Hyuck; G.W. Quek, Ruben; Markova, Denka; Cristina Tudor, Iulia; L. Hannah, Alison; Eiermann, W.; L. Blum, Joanne

doi:10.1056/nejmoa1802905

Public

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Published in New England Journal of Medicine • Aug 15, 2018

Authors:

Jennifer K. Litton

Hope S. Rugo

Johannes Ettl

Abstract

BACKGROUND: The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 ( BRCA1/2). METHODS: We conducted a randomized, open-label, phase 3 trial in which patients with advanced breast can...

Subject

Medicine

Hazard ratio

Eribulin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!